

Malaysian Genomics explores distribution of biopharma, genetic screening services in MENA

29 August 2022 | News

Inks MoU with Ajlan & Bros Medical Company

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.

Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.

As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products.

Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantations, healthcare and industrial biotechnology.

Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.